Drug Approval | June 01, 2026
Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial
The therapy also delivered significant improvements in key liver enzyme markers
The therapy also delivered significant improvements in key liver enzyme markers
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
The approval marks a major milestone in the global fight against antimicrobial resistance
The company is building a connected healthcare ecosystem that utilises smart healthcare kiosk and mobile app to deliver at-home, AI-assisted health screenings and non-invasive health measurements
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
Subscribe To Our Newsletter & Stay Updated
